Related Experiment Videos
Current management strategies for cutaneous T-cell lymphoma
1Columbia University College of Physicians and Surgeons, New York, New York, USA. ehk3@columbia.edu
Clinics in Dermatology
|July 21, 2004
Summary
Cutaneous T-cell lymphoma (CTCL) involves malignant T cells in the skin. Early-stage CTCL responds well to skin-directed therapies, while advanced or resistant cases require more intensive treatments for remission.
Area of Science:
- Dermatology
- Oncology
- Immunology
Background:
- Cutaneous T-cell lymphoma (CTCL) is a diverse group of malignant lymphomas.
- Characterized by the proliferation of T lymphocytes that home to the skin.
- Prognosis varies, with treatment tailored to disease stage and the goal of remission.
Purpose of the Study:
- To outline current treatment strategies for Cutaneous T-cell lymphoma.
- To differentiate therapeutic approaches based on disease stage (early vs. advanced).
- To review various treatment modalities for CTCL.
Main Methods:
- Review of established and emerging therapies for CTCL.
- Categorization of treatments by disease extent and resistance.
- Discussion of topical agents, phototherapy, radiation, systemic therapies, and transplantation.
Main Results:
- Early-stage CTCL (patches, plaques) responds well to skin-directed therapies.
- Topical agents (corticosteroids, nitrogen mustard, bexarotene gel) and phototherapy are effective.
- Advanced or resistant CTCL necessitates aggressive treatments like radiation, biologics, or stem cell transplantation.
Conclusions:
- Treatment selection for CTCL is stage-dependent, aiming for remission.
- Skin-directed therapies offer good outcomes for early-stage disease.
- Multimodal and aggressive approaches are crucial for advanced or refractory CTCL.